国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (4): 238-240.doi: 10.3760/cma.j.issn.1673-422X.2018.04.012

• 综述 • 上一篇    下一篇

二代免疫检查点抑制剂的研究进展

 张百红,岳红云   

  1. 730050 兰州军区兰州总医院肿瘤科（张百红），眼科（岳红云）
  • 出版日期:2018-04-08 发布日期:2018-05-16
  • 通讯作者: 张百红，Email: bhzhang1999@126.com E-mail:bhzhang1999@126.com
  • 基金资助:

    甘肃省自然科学基金（1308RJZA181）

Advances of next-generation immune checkpoint blockade

Zhang Baihong, Yue Hongyun   

  1. Department of Oncology, Lanzhou General Hospital of Lanzhou Military Region, Lanzhou 730050, China
  • Online:2018-04-08 Published:2018-05-16
  • Contact: Zhang Baihong, Email: bhzhang1999@126.com E-mail:bhzhang1999@126.com
  • Supported by:

    Natural Science Foundation of Gansu Province of China (1308RJZA181)

PDF

1389

摘要： 免疫检查点抑制剂可持续诱导免疫反应，但抗体大分子本身存在缺陷，对免疫抑制细胞的忽视使其仅对一小部分肿瘤患者有效。二代免疫检查点抑制剂包括结合Fcγ受体的抗程序性死亡受体（PD）-1/PD配体1（PD-L1）抗体、双免疫检查点抗体、小分子免疫检查点抑制剂和PD-1/PD-L1抗体耦联药物，其克服了一代抗PD-1/PD-L1抗体的不足，将成为未来免疫治疗的新方向。

关键词: 肿瘤, 治疗, 变态反应和免疫学

Abstract: Immune checkpoint blockades can induce long lasting responses but only in a fraction of patients owing to deficient of antibody as well as the neglect of immune suppressive cells. Nextgeneration immune checkpoint blockades, including FcγR-binding anti-programmed cell death-1 (PD-1）/PD ligand 1 (PD-L1) antibodies, coinhibitors of immune checkpoint, small-molecule modulators and antibody-drugs conjugated with PD-1/PD-L1, will overcome the deficiencies of current antiPD-1/PD-L1 antibodies and will become the direction of immunotherapy in the future.

Key words: Neoplasms, Therapy, Allergy and immunology